Results of the breast cancer population screening circuit at the San Carlos Clinical Hospital
e202006050
Keywords:
Breast cancer, Screening, Mammography, BIRADSAbstract
Background: The objective of the study was to compare the time difference between diagnose and treatment with relation to switching protocols in screening program, DEPRECAM; and to analyze the screening program over our sample.
Methods: It is a retrospective study involving 173 patients with two no time concurrent clinical cohorts referred from DEPRECAM program to San Carlos Clinic Hospital (HCSC) between March 2017 and January 2019. It was compared the time differences between the group forwarded to Breast Pathology service (Group A; n=92) and the group directly forwarded to Radiology department (Group B; n=81), using the non-parametric Mann-Whitney U test, estimating the difference of the means together with its 95% confidence interval.
Results: The averaged time to final diagnosis for group A and group B was 38.55 and 35.01 days respectively; and averaged time to treatment was 102.46 and 95.6 days. The difference between groups was not statistically significant (diagnosis p=0.999; treatment p=0.451). The correlation between sizes recognized in imaging test was reasonable. The consistency between imaging test and Histopathology was weak.
Conclusions: The change in protocol does not reduce time significantly.
Downloads
References
Evolución del cáncer de mama [Internet]. Aecc.es.
Natal Ramos C. Efectividad y eficiencia en los programas poblacionales de cribado de cáncer de mama. Instituto Universitario de Oncología, IUOPA; 2017. Disponible en: http://hdl.handle.net/10651/44583.
Detección precoz del cáncer de mama [Internet]. Madrid.org.
Paci E. Summary of the Evidence of Breast Cancer Service Screening Outcomes in Europe and First Estimate of the Benefit and Harm Balance Sheet. Journal of Medical Screening. 2012;19(1_suppl):5-13.
Tosteson A, Fryback D, Hammond C, Hanna L, Grove M, Brown M et al. Consequences of False-Positive Screening Mammograms. JAMA Internal Medicine. 2014;174(6):954.
Welch H, Prorok P, O’Malley A, Kramer B. Breast-Cancer Tumor Size, Overdiagnosis, and Mammography Screening Effectiveness. New England Journal of Medicine. 2016;375(15):1438-1447.
Marzo-Castillejo M, Vela-Vallespín C. Sobrediagnóstico en cáncer. Atención Primaria. 2018; 50:51-56.
Lannin D, Wang S. Are Small Breast Cancers Good because They Are Small or Small because They Are Good? New England Journal of Medicine. 2017;376(23):2286-91.
Smith E, Ziogas A, Anton-Culver H. Delay in Surgical Treatment and Survival After Breast Cancer Diagnosis in Young Women by Race/Ethnicity. JAMA Surgery. 2013;148(6):516.
Bleicher R. Timing and Delays in Breast Cancer Evaluation and Treatment. Annals of Surgical Oncology. 2018;25(10):2829-2838.
Caplan L. Delay in Breast Cancer: Implications for Stage at Diagnosis and Survival. Frontiers in Public Health. 2014;2.
Neal R. Do diagnostic delays in cancer matter?. British Journal of Cancer. 2009;101(S2):S9-S12.
Mira J, Pérez-Jover V, Ibañez J, Guilabert M, Cuevas D, Salas D. Calidad de la atención al paciente oncológico: Tiempos asistenciales recomendables entre sospecha clínica y definición del plan terapéutico en cáncer de mama y colorrectal. 2019.
Pérez G, Porta M, Borrell C, Casamitjana M, Bonfill X, Bolibar I et al. Interval from diagnosis to treatment onset for six major cancers in Catalonia, Spain. Cancer Detection and Prevention. 2008;32(3):267-275.
Gilbert F, Pinker-Domenig K. Diagnosis and Staging of Breast Cancer: When and How to Use Mammography, Tomosynthesis, Ultrasound, Contrast-Enhanced Mammography, and Magnetic Resonance Imaging. Communications in Computer and Information Science. 2019:155-166.
Pop C, Stanciu-Pop C, Drisis S, Radermeker M, Vandemerckt C, Noterman D et al. The impact of breast MRI workup on tumor size assessment and surgical planning in patients with early breast cancer. The Breast Journal. 2018;24(6):927-933.
Katz B, Raker C, Edmonson D, Gass J, Stuckey A, Rizack T. Predicting Breast Tumor Size for Pre-operative Planning: Which Imaging Modality is Best?. The Breast Journal. 2016;23(1):52-58.
Rashmi S, Kamala S, Murthy S, Kotha S, Rao Y, Chaudhary K. Predicting the molecular subtype of breast cancer based on mammography and ultrasound findings. Indian Journal of Radiology and Imaging. 2018;28(3):354.
Jiménez Yáñez R. Correlación radio patológica en las lesiones BIRADS 4b. Nuestra experiencia. ¿Lo estamos haciendo bien? ¿Cómo podemos mejorar? [Internet]. SERAM. 2017.
Downloads
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2020 Miriam de la Puente Yagüe, María José Ciudad Fernández, Alejandra Mayoral Triana, Myriam Montes Fernández, María Herrera de la Muela
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Usted es libre de:
Compartir — copiar y redistribuir el material en cualquier medio o formato.
La licenciante no puede revocar estas libertades en tanto usted siga los términos de la licencia.
Bajo los siguientes términos:
Atribución — Usted debe dar crédito de manera adecuada , brindar un enlace a la licencia, e indicar si se han realizado cambios. Puede hacerlo en cualquier forma razonable, pero no de forma tal que sugiera que usted o su uso tienen el apoyo de la licenciante.
NoComercial — Usted no puede hacer uso del material con propósitos comerciales.
SinDerivadas — Si remezcla, transforma o crea a partir del material, no podrá distribuir el material modificado.
No hay restricciones adicionales — No puede aplicar términos legales ni medidas tecnológicas que restrinjan legalmente a otras a hacer cualquier uso permitido por la licencia.
Avisos:
No tiene que cumplir con la licencia para elementos del material en el dominio público o cuando su uso esté permitido por una excepción o limitación aplicable.
No se dan garantías. La licencia podría no darle todos los permisos que necesita para el uso que tenga previsto. Por ejemplo, otros derechos como publicidad, privacidad, o derechos morales pueden limitar la forma en que utilice el material.
